atai Life Sciences Announces First Subject Dosed in Phase 1 Trial...

MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S-...

KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle...

Interview | George Tziras, Small Pharma

Combating Suicidality: A Role for Psilocybin and Ayahuasca?

PT361 – Jason Slot, Ph.D. – Mycology and Evolutionary Genomics

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released...

Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common...

Psychedelic Bulletin #119: More Misery for MindMed; Another Psychedelics Co. Ceases...

Load more